학술논문
154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer
Document Type
Abstract
Author
Source
In ESMO Open May 2023 8(1) Supplement 4
Subject
Language
ISSN
2059-7029